dl 111-it has been researched along with cyclin d1 in 1 studies
| Studies (dl 111-it) | Trials (dl 111-it) | Recent Studies (post-2010) (dl 111-it) | Studies (cyclin d1) | Trials (cyclin d1) | Recent Studies (post-2010) (cyclin d1) |
|---|---|---|---|---|---|
| 38 | 0 | 1 | 10,885 | 70 | 5,157 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, RY; He, QJ; Lou, YJ; Yang, B | 1 |
1 other study(ies) available for dl 111-it and cyclin d1
| Article | Year |
|---|---|
Contragestazol (DL111-IT) inhibits proliferation of human androgen-independent prostate cancer cell line PC3 in vitro and in vivo.
Topics: Androgens; Animals; Cell Division; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase 4; Dose-Response Relationship, Drug; Female; G1 Phase; Humans; Immunosuppressive Agents; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Prostatic Neoplasms; Resting Phase, Cell Cycle; Retinoblastoma Protein; Transplantation, Heterologous; Triazoles | 2005 |